Metropolitan Life Insurance Co NY grew its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 5.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,670 shares of the biopharmaceutical company’s stock after buying an additional 174 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in SAGE Therapeutics were worth $583,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc lifted its stake in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares in the last quarter. SG Americas Securities LLC grew its holdings in SAGE Therapeutics by 31.5% in the 4th quarter. SG Americas Securities LLC now owns 3,385 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 810 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of SAGE Therapeutics during the 4th quarter valued at about $259,000. California Public Employees Retirement System boosted its stake in shares of SAGE Therapeutics by 3.4% during the 4th quarter. California Public Employees Retirement System now owns 62,600 shares of the biopharmaceutical company’s stock valued at $5,996,000 after purchasing an additional 2,055 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of SAGE Therapeutics by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 273,407 shares of the biopharmaceutical company’s stock valued at $26,190,000 after purchasing an additional 6,539 shares in the last quarter.
In other news, SVP Anne Marie Cook sold 15,000 shares of SAGE Therapeutics stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $166.14, for a total value of $2,492,100.00. Following the completion of the sale, the senior vice president now directly owns 15,000 shares in the company, valued at $2,492,100. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $162.22, for a total transaction of $1,297,760.00. Following the completion of the sale, the director now owns 12,235 shares of the company’s stock, valued at $1,984,761.70. The disclosure for this sale can be found here. Insiders sold 226,925 shares of company stock valued at $39,438,777 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.
SAGE Therapeutics stock traded down $1.28 during trading hours on Friday, hitting $184.54. The stock had a trading volume of 286,544 shares, compared to its average volume of 319,058. The company has a debt-to-equity ratio of 0.03, a current ratio of 20.06 and a quick ratio of 20.06. The company has a market cap of $9.44 billion, a PE ratio of -22.84 and a beta of 2.54. SAGE Therapeutics Inc has a 12-month low of $79.88 and a 12-month high of $193.56. The stock has a 50-day simple moving average of $179.31.
SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.17) by ($0.20). The business had revenue of $0.47 million for the quarter. During the same period in the previous year, the firm earned ($1.68) earnings per share. As a group, equities analysts forecast that SAGE Therapeutics Inc will post -13.19 earnings per share for the current fiscal year.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Featured Article: What is the QQQ ETF?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.